Cargando…

The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy

Antibodies against checkpoint inhibitors such as anti-programmed cell death protein 1 (PD-1) and its ligand anti-programmed death ligand 1 (PD-L1) have shown clinical efficacy in the treatment of multiple cancers. However, there are only a few studies on biomarkers for these targeted immunotherapies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Liangliang, Xie, Shengzhi, Wang, Lingxiong, Li, Jinfeng, Han, Lu, Qin, Boyu, Zhang, Guoqing, Wu, Qiyan, Gao, Wenjuan, Zhang, Lijun, Wei, Huafeng, Liu, Tianyi, Jiao, Shunchang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072287/ https://www.ncbi.nlm.nih.gov/pubmed/33912192 http://dx.doi.org/10.3389/fimmu.2021.665147

Ejemplares similares

The level of macrophage migration inhibitory factor is negatively correlated with the efficacy of PD-1 blockade immunotherapy combined with chemotherapy as a neoadjuvant therapy for esophageal squamous cell carcinoma
por: Wu, Liangliang, et al.
Publicado: (2023)

A nomogram-based immunoprofile predicts clinical outcomes for stage II and III human colorectal cancer
por: Wang, Lingxiong, et al.
Publicado: (2021)

Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy
por: Liu, Hongyu, et al.
Publicado: (2017)

Bioinformatic Analysis of Hepatocellular Carcinoma Cell Lines to the Efficacy of Nimotuzumab
por: Wang, Yu, et al.
Publicado: (2021)

A hypoxia- and lactate metabolism-related gene signature to predict prognosis of sepsis: discovery and validation in independent cohorts
por: Peng, Yaojun, et al.
Publicado: (2023)

A DNA methylation signature to improve survival prediction of gastric cancer
por: Peng, Yaojun, et al.
Publicado: (2020)

Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma
por: Shen, Shaoping, et al.
Publicado: (2020)

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy
por: Gao, Yiming, et al.
Publicado: (2022)

Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers
por: Li, Ye, et al.
Publicado: (2021)

Identification of Immune-Related Genes Concurrently Involved in Critical Illnesses Across Different Etiologies: A Data-Driven Analysis
por: Peng, Yaojun, et al.
Publicado: (2022)

miR-409 Inhibits Human Non-Small-Cell Lung Cancer Progression by Directly Targeting SPIN1
por: Song, Qi, et al.
Publicado: (2018)

Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma
por: Peng, Yaojun, et al.
Publicado: (2023)

Ascites-derived IL-6 and IL-10 synergistically expand CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in ovarian cancer patients
por: Wu, Liangliang, et al.
Publicado: (2017)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

PD-1(+) mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
por: Li, Jun, et al.
Publicado: (2022)

Nomogram for predicting survival in patients with advanced hepatocellular carcinoma treated with PD-1 inhibitors: incorporating pre-treatment and post-treatment clinical parameters
por: Jia, Guhe, et al.
Publicado: (2023)

A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy
por: Duan, Jingjing, et al.
Publicado: (2018)

Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients
por: Qiu, Lupeng, et al.
Publicado: (2020)

Allogeneic cell-based immunotherapy combined with chemotherapy and targeted therapy in advanced pancreatic cancer with metastases: A case report
por: LONG, YANYAN, et al.
Publicado: (2014)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
por: Shi, Fei, et al.
Publicado: (2018)

The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
por: Shi, Fei, et al.
Publicado: (2017)

Analysis of human glioma-associated co-inhibitory immune checkpoints in glioma microenvironment and peripheral blood
por: Shen, Shaoping, et al.
Publicado: (2021)

The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC
por: Cai, Yang, et al.
Publicado: (2015)

Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial
por: Zhang, Guoqing, et al.
Publicado: (2023)

An immune-related gene signature predicts the 28-day mortality in patients with sepsis
por: Peng, Yaojun, et al.
Publicado: (2023)

Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
por: Wei, Huafeng, et al.
Publicado: (2014)

Case Report: Pseudoprogression With Nivolumab and Bevacizumab Followed by Recurrent Immune-Related Pneumonitis in Urothelial Carcinoma With Lung Metastasis
por: Yang, Zizhong, et al.
Publicado: (2021)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data
por: Wang, Zhenxin, et al.
Publicado: (2020)

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
por: Hinterleitner, Clemens, et al.
Publicado: (2021)

Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer
por: Zang, Yuan‐sheng, et al.
Publicado: (2019)

Human iPS Cells Loaded with MnO(2)-Based Nanoprobes for Photodynamic and Simultaneous Enhanced Immunotherapy Against Cancer
por: Liu, Yanlei, et al.
Publicado: (2020)

Driver gene alterations profiling of Chinese non‐small cell lung cancer and the effects of co‐occurring alterations on immunotherapy
por: Sun, Shengjie, et al.
Publicado: (2021)

Predictive Biomarkers of Dicycloplatin Resistance or Susceptibility in Prostate Cancer
por: Liu, Minglu, et al.
Publicado: (2021)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
por: Sun, Jin-Yu, et al.
Publicado: (2020)

Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer
por: Lu, Lu, et al.
Publicado: (2022)

Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy
por: Jiang, Mingxia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ed8ea3vseg5vacgsfa8c6k4b1b